pacritinib
pacritinib: sourced relationships with 1 company · 8 clinical trials tracked.
pacritinib evidence translation
What we can confirm
8 tracked trials
What it means
What to watch
Prepared research question
How could pacritinib → CTIC affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence5 indications · 1 study sponsors
Related indications
Study sponsors
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| CTI BIOPHARMA CORP (CTIC) Severe COVID-19 | Phase 3 |
Clinical Trial Registry Records (8)
A Pilot Study of Pacritinib Combined With a BTK Inhibitor in Patients With Relapsed/Refractory Mantle Cell Lymphoma
Primary endpoint: Incidence of adverse events (AEs)
A Phase 1/2 Study of Pacritinib in Combination With Azacitidine for the Treatment of IPSS-M Moderate Low to Very High Risk Myelodysplastic Syndrome
Primary endpoint: Optimal Dose of Pacritinib in Combination with Azacitidine - Phase 1
Investigator-Initiated, Open-Label, Phase II Trial of Selinexor in Combination With Pacritinib in Patients With Myelofibrosis Who Are JAK Inhibitor-Naïve and Have Cytopenias (ILLUMINATE)
Primary endpoint: Change in spleen volume
A Phase 2 Trial Investigating the Addition of Pacritinib to a Hypomethylating Agent as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant in Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms
Primary endpoint: Number of patients who receive hematopoietic stem cell transplant
A Phase Ib/II Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic and Efficacy Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung Adenocarcinoma
Primary endpoint: Progression Free Survival (PFS)
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
Primary endpoint: Proportion of Participants with Spleen Volume Reduction ≥35% (SVR35) at Week 24
Phase 2, Open Label, Multicenter Study of Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms
Primary endpoint: Overall response rate (ORR)
A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression
Primary endpoint: STAT Activity
Frequently asked questions
Which companies have sourced relationships with pacritinib?
pacritinib has dated SEC/FDA relationship records for CTI BIOPHARMA CORP.
How many clinical trials involve pacritinib?
BioSniper tracks 8 clinical trials involving pacritinib.